FUL Offers $943M for AMS

B. Fuller Company (NYSE: FUL ) shares traded lower in Thursday’s premarket session as investors weighed its recommended cash offer for Advanced Medical Solutions Group plc and second-quarter results that beat estimates and raised guidance. B. 29 million).

Advanced Medical Solutions is a differentiated medical products company with surgical adhesive technologies. It has an innovation-led platform, global commercial footprint, R&D capabilities, and regulatory expertise. B. Fuller Expectations Ahead Of Q2 Earnings The fully financed transaction is expected to close by year-end, subject to approvals and customary closing conditions.

B. Fuller stated that the acquisition will expand its presence in medical adhesives and related healthcare products, such as tissue-bonding adhesives, tapes, dressings, and formulated biosurgicals. The company expects AMS to contribute approximately $300 million in annual revenue and expand its total addressable market by $15 billion to $95 billion. It also anticipates about $55 million, or 41 million pounds, in annual run-rate revenue and cost synergies by 2031.

B. Fuller stated that the deal supports its long-term targets of 5% annual constant currency revenue growth and EBITDA margins above 20%. 5 to 3 times within two years after closing. B.

Fuller President and CEO Celeste Mastin said. B. Fuller raised the midpoint of its full-year adjusted EBITDA and adjusted EPS guidance. 8 million estimate.

6%, with pricing gains offsetting a slight decline in volume. Net income reached $68 million. 40 estimate. 2%, primarily due to effective pricing and restructuring savings.

Cash Flow, Debt, and Guidance Operating cash flow reached a record $121 million for the second quarter, up approximately 10% year-over-year. The company also repurchased 750,000 shares during the quarter. B. 10 million.

4x. 84 estimate. B. 50 during premarket trading on Thursday, according to Pro data.

Photo via Shutterstock